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Özet
Amaç: Bu çalışmada Tavşanlı Devlet Hastanesi Mikrobiyoloji Laboratuvarı’na 
gönderilen çeşitli klinik örneklerden izole edilen Acinetobacter baumanii suş-
larının antibiyotik duyarlılıklarının retrospektif olarak incelenmesi amaçlandı. 
Gereç ve Yöntem: Kültürlerin tümü etken ve antibiyotik duyarlılıkları açısın-
dan irdelenmiştir. Bakterilerin tanımlanmasında çeşitli biyokimyasal testler 
ve BBL Crystal E/NF (Beckton Dickinson, ABD) sistemi kullanılmıştır. Antibi-
yotik duyarlılığı Mueller-Hinton Agarda disk diffüzyon yöntemi ile CLSI kriter-
leri doğrultusunda değerlendirilmiştir. Bulgular: Acinetobacter baumanii ola-
rak izole ve identifiye edilen suş sayısı 74 idi. Suşların çoğunluğu trakeal as-
pirat örneklerinden izole edildi (%46). Suşların çoğunluğu nozokomiyal infek-
siyonlardan izole edildi(% 93). Suşların antibiyotik direnci yüksek bulundu. En 
duyarlı antibiyotik ise gentamisindi (%30). Sonuç: Direnç gelişimini önlemek 
için antibiyotikler uygun doz ve sürede dikkatlice kullanılmalı, ampirik teda-
vi, her merkez için kendi direnç oranlarına göre belirlenmeli, ve antibiyogram 
sonucuna göre düzenlenmelidir. Artan direnç oranları Acinetobacter suşlarına 
karşı yeni alternatif antibiyotik kullanımına neden olmaktadır.
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Abstract
Aim: In this study it was aimed to investigate the antibiotic susceptibilities 
of Acinetobacter baumanii strains isolated from various clinical samples sent 
to Tavsanli State Hospital Microbiology Laboratory retrospectively. Material 
and Method: All of the cultures were examined for the agent and antibiotic 
susceptibilities.  For  the  identification  of  bacteria,  various  chemical  tests 
and BBL Crystal E/NF (Beckton Dickinson, ABD) system was used. Antibiotic 
susceptibilities  were  investigated  according  to  CLSI  criteria  on  Mueller 
Hinton agar by disc diffusion method. Results: There were 74 strains isolated 
and identified as Acinetobacter baumanii. Most of the strains were isolated 
from tracheal aspirate specimens (46 %) Most of the strains were isolated 
from  nosocomial infections. Antibiotic resistance was high among strains. 
The  most  susceptible  antibiotic  was  gentamicin  (30%).  Discussion:  To 
prevent the development of resistance, antibiotics should be used carefully in 
appropriate doses and time, empirical antibiotherapy should be determined 
for each centre according to resistance rates of the centre and should be 
regulated according to the antibiogram results. Increasing resistance rates 
in Acinetobacter strains leads to the usage of new alternative antibiotics.
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Introduction
Acinetobacter species, which are found in soil and animals can 
cause  nosocomial  infections,  which  are  seen  more  frequent 
than community acquired infections in hospitals [1]. Its great 
capacity to  survive in low-moist environment and its ability to 
develop resistance to antimicrobial agents afford Acinetobacter 
baumanii the possibility of spreading in hospitals. The risk of 
colonization and subsequent infection are associated with fac-
tors such as the presence of underlying severe illnesses, long 
term hospitalization, stays in spesific hospital wards, selective 
antimicrobial pressure and invasive interventions such as the 
use of mechanical ventilation or catheters [2-4].
Acinetobacter  infections  are  usually  seen  in  intensive  care 
units (ICU). Acinetobacter species are colonized over mechani-
cal instruments, colonized on health care workers and patients, 
selected by antibiotic usage and becomes the reason of noso-
comial infections [5]. Acinetobacter species are the reason of 
bacterial  colonization,  bacteremia,  pneumoniae,  urinary  tract 
infections, wound infections  [6]. In this study it was aimed to in-
vestigate the antibiotic susceptibilities and extended spectrum 
beta lactamase production of Acinetobacter baumanii strains 
isolated from miscellaneous clinical samples sent to Tavsanli 
State Hospital Microbiology Laboratory retrospectively.
Material and Method
In this study microbiogical samples sent to Tavsanli State Hospi-
tal Microbiology Laboratory between January 2010 and Decem-
ber 2011 were evaluated. All of the cultures were examined for 
the agent and antibiotic susceptibilities. For the identification 
of bacteria, various chemical tests and BBL Crystal E/NF (Beck-
ton Dickinson, ABD) system was used. Antibiotic susceptibilities 
were investigated according to CLSI criteria on Mueller Hinton 
agar by disc diffusion method. Ampicillin, cefazolin, cefuroxime, 
ceftriaxone,  ceftazidime,  imipenem,    piperacillin/tazobactam, 
sulbactam/cefoperazone, sulbactam/ampicillin,  trimethoprim/
sulfamethoxazole, amikacin, gentamicin and ciprofloxacin was 
investigated for antibiotic susceptibility [7].
Results
There were 74 strains isolated and identified as Acinetobacter 
baumanii. Most of the strains were isolated from tracheal as-
pirate specimens (%46) (Table 1). Only five of the isolates were 
from community acquired infections (%7), 69 strains were  from   
nosocomial infections. 64 strains were isolated from the sam-
ples sent from the intensive care unit. Antibiotic resistance was 
high among strains (Table 2). The most susceptible antibiotic 
was gentamicin (%30).
Discussion
Acinetobacter strains are one of the most common bacteria 
isolated from nosocomial  infections [8]. In recent years, the 
species has emerged as particularly important in nosocomial 
infections in ICUs probably related to the increasingly invasive 
diagnostic procedures used and the increasingly greater quan-
tity of broad-spectrum antimicrobials used. Development of re-
sistance against antimicrobials is a major problem in treatment 
of Acinetobacter infections. Although their virulence is low they 
rapidly acquire resistance [9].  
In Spain between 1991 and 1996, 1532 Acinetobacter strains 
were investigated for antimicrobial resistance. Resistance rates 
increased in time; imipenem resistance increased to % 80 from 
%1, ciprofloxacine increased to %90 from %54, amikacin in-
creased to % 84 from %21, ampicillin/sulbactam increased to % 
84 from % 66 [10]. Dobrewski et al. [11], investigated 18 multi 
drug resistant Acinetobacter strains isolated from surgical in-
tensive care unit. % 89 of the strains were resistant against, 
piperacillin, ceftasidime, gentamicin, ciprofloxacin.
Yurtsever et al. [12], investigated 120 Acinetobacter strains in 
2007. % 50 of the isolates were from ICUs. Susceptibility rates 
were; %10 against ceftasidime, % 18 against ciprofloxacin, % 
66 against ampicillin/sulbactam, % 14 against trimethoprim/
sulfamethoxazole, % 63 against amikacin, % 65 against imipe-
nem,  %87 against sulbactam/cefoperazone.
Balci et al. [13], investigated 79 Acinetobacter strains isolated 
between 2005 and 2007. They found that the % 63 of the sam-
ples were sent from ICUs and most of the isolates were from 
respiratory tract samples (%43).  Susceptibility rates were; %1 
against ceftasidime, % 18 against ciprofloxacin, % 19 against 
ampicillin/sulbactam, % 22 against trimethoprim/sulfamethox-
azole, % 34 against amikacin and % 51 against imipenem.
Ozdemir  et  al.  [8],  investigated  215  Acinetobacter  baumanii 
strains for antimicrobial susceptibility in 2008. %78 of the bac-
teria were isolated from the sapmples from ICUs. % 42 of the 
samples  were  respiratory  specimens.  Susceptibilities  against 
ceftasidime was %11, ciprofloxacin was %14, gentamicin was 
% 18, imipenem was % 40 and  sulbactam/cefoperazone was 
% 60. Susceptibility against tigecycline was % 99 and colistin 
Table 1. Distribution of samples isolated from clinical specimens
(n: number of specimens)
Clinical specimen n %
Tracheal aspirate 34 46
Urine 32 43
Wound 5 7
Catheter 3 4
Total 74 100
Table 2. Susceptibility rates of Acinetobacter baumanii strains according to 
the origin of the strains (n: number of isolates, SAM: sulbactam/ampicillin, 
SCF:  sulbactam/cefoperazone,  SXT:  trimethoprim/sulfamethoxazole,  TZP: 
piperacillin/tazobactam).
Antibiotic Community acquired
(n=5) %
Nosocomial
(n=69) %
Total
(n=74) %
Ampicillin 0 0 0
Cefazolin 0 0 0
Cefuroxime 0 0 0
Ceftriaxone 0 0 0
Ceftazidime 20 1 3
Imipenem 40 12 14
TZP 40 0 3
SCF 80 14 19
SAM 40 7 9
SXT 60 13 16
Amikacin 20 6 7
Gentamicin 80 26 30
Ciprofloxacin 20 2 3
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was % 100. Tigecycline and colistin were investigated in the 
last nine Acinetobacter isolates in our laboratory. All of them 
were found susceptible against colistin, and all of them were 
resistant against tigecycline.  
Mansur et al [14] isolated 147 Acinetobacter strains in 2008 in 
a tertiary care hospital. %32 of the samples were from ICU’s. 
Most frequent samples were tracheal aspirate (%29) and blood 
(%26).  Tigecycline  was  found  the  most  effective  antibiotic, 
against which the strains were %100 susceptible. Colistin sus-
ceptibility was found to be %91. Susceptibilities against imipe-
nem, amikacin, gentamicin, ceftasidime and ciprofloxacin were; 
% 38, % 14, % 21, %9 and %11 respectively.
Kurtoglu et al. [6], inspected the resistance rates between 2008 
and 2010 in Acinetobacter strains. They found that the resis-
tance rates were inreasing in trimethoprim/sulfamethoxazole, 
imipenem,    piperacillin/tazobactam  and  sulbactam/cefopera-
zone by time.
Colistin and tigecycline are new alternatives in the treatment of 
Acinetobacter strains. Gales et al. [15] investigated polymyxine 
resistance in 2621 strains. They found the resistance against 
polymyxine % 2,1. But the side effects of colistin restricts the 
use of the drug. Tigecycline which is a minocycline derivative is 
another effective choice against Acinetobacter strains. Tigecy-
cline susceptibility is usually over %90 in acinetobacter strains 
[16,17].
To avoid resistance, antibiotics should be used carefully in ap-
propriate doses and time, empirical antibiotherapy should be 
determined for each centre according to resistance rates of the 
centre and should be regulated according to the antibiogram re-
sults. Increasing resistance rates in Acinetobacter strains leads 
to the usage of new alternative antibiotics.
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